Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway

Cancer

Volumn 118, Issue 23, 2012, Pages 5757-5767

  Cheng, Tsu Yao ^a,b   Wu, Ming Shiang ^b   Lin, Jaw Town ^b   Lin, Ming Tsan ^b   Shun, Chia Tung ^b   Huang, Hsin Yi ^b   Hua, Kuo Tai ^a   Kuo, Min Liang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

annexin A1; cancer invasion; formyl peptide receptor; gastric cancer; survival

Indexed keywords

BINDING PROTEIN; FORMYLPEPTIDE RECEPTOR; INTEGRIN BETA 1 BINDING PROTEIN 1; LIPOCORTIN 1; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; ANNEXIN A1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RECEPTORS, FORMYL PEPTIDE; STOMACH NEOPLASMS;

EID: 84869506420     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27565     Document Type: Article

References (43)

1. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E,. Gastric cancer. Crit Rev Oncol Hematol. 2009; 71: 127-164.
3. Inoue M, Tsugane S,. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005; 81: 419-424. (Pubitemid 41002579)
4. Liakakos T, Roukos DH,. More controversy than ever-challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008; 15: 956-960.
5. Wu MS, Lin YS, Chang YT, Shun CT, Lin MT, Lin JT,. Gene expression profiling of gastric cancer by microarray combined with laser capture microdissection. World J Gastroenterol. 2005; 11: 7405-7412.
6. Wu CM, Lee YS, Wang TH, et al. Identification of differential gene expression between intestinal and diffuse gastric cancer using cDNA microarray. Oncol Rep. 2006; 15: 57-64.
7. Jinawath N, Furukawa Y, Hasegawa S, et al. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene. 2004; 23: 6830-6844. (Pubitemid 39280016)
8. Gerke V, Moss SE,. Annexins: from structure to function. Physiol Rev. 2002; 82: 331-371. (Pubitemid 34654456)
9. Perretti M, D'Acquisto F,. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009; 9: 62-70.
10. Williams SL, Milne IR, Bagley CJ, et al. A proinflammatory role for proteolytically cleaved annexin A1 in neutrophil transendothelial migration. J Immunol. 2010; 185: 3057-3063.
11. Lim LH, Pervaiz S,. Annexin 1: the new face of an old molecule. FASEB J. 2007; 21: 968-975. (Pubitemid 46495688)
12. Mussunoor S, Murray GI,. The role of annexins in tumour development and progression. J Pathol. 2008; 216: 131-140.
13. Xue LY, Teng LH, Zou SM, et al. Expression of annexin I in different histological types of carcinomas. Zhonghua Zhong Liu Za Zhi. 2007; 29: 444-448.
14. Yu G, Wang J, Chen Y, et al. Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis. 2008; 25: 695-702.
15. Migeotte I, Communi D, Parmentier M,. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 2006; 17: 501-519. (Pubitemid 44793122)
16. Walther A, Riehemann K, Gerke V,. A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell. 2000; 5: 831-840.
17. Perretti M, Chiang N, La M, et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med. 2002; 8: 1296-1302. (Pubitemid 35373563)
18. Alldridge LC, Harris HJ, Plevin R, Hannon R, Bryant CE,. The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem. 1999; 274: 37620-37628. (Pubitemid 30026818)
19. Alldridge LC, Bryant CE,. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp Cell Res. 2003; 290: 93-107. (Pubitemid 37153254)
20. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.
21. Lin MT, Chang CC, Lin BR, et al. Elevated expression of Cyr61 enhances peritoneal dissemination of gastric cancer cells through integrin alpha2beta1. J Biol Chem. 2007; 282: 34594-34604.
22. Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M,. Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer. 1996; 74: 1406-1412. (Pubitemid 26370731)
23. Ura H, Denno R, Hirata K, Yamaguchi K, Yasoshima T,. Separate functions of alpha2beta1 and alpha3beta1 integrins in the metastatic process of human gastric carcinoma. Surg Today. 1998; 28: 1001-1006.
24. Takatsuki H, Komatsu S, Sano R, Takada Y, Tsuji T,. Adhesion of gastric carcinoma cells to peritoneum mediated by alpha3beta1 integrin (VLA-3). Cancer Res. 2004; 64: 6065-6070. (Pubitemid 39129405)
25. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS,. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000; 87: 236-242. (Pubitemid 30088655)
26. Duncan R, Carpenter B, Main LC, Telfer C, Murray GI,. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 2008; 98: 426-433. (Pubitemid 351161239)
27. Wang KL, Wu TT, Resetkova E, et al. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006; 12: 4598-4604. (Pubitemid 44297810)
28. Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA,. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol. 2003; 162: 255-261. (Pubitemid 36042007)
29. Hu N, Flaig MJ, Su H, et al. Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res. 2004; 10: 6013-6022. (Pubitemid 39302608)
30. Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME,. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004; 13: 667-672. (Pubitemid 38737907)
31. Saper CB, Sawchenko PE,. Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. J Comp Neurol. 2003; 465: 161-163. (Pubitemid 37100126)
32. Babbin BA, Lee WY, Parkos CA, et al. Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem. 2006; 281: 19588-19599. (Pubitemid 44035462)
33. Yi M, Schnitzer JE,. Impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1-null mice. Proc Natl Acad Sci U S A. 2009; 106: 17886-17891.
34. Reddy KB, Nabha SM, Atanaskova N,. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003; 22: 395-403. (Pubitemid 36791895)
35. Liebmann C,. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal. 2001; 13: 777-785. (Pubitemid 32913686)
36. Zhou Y, Bian X, Le Y, et al. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst. 2005; 97: 823-835. (Pubitemid 40909125)
37. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M,. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood. 2006; 107: 2123-2130. (Pubitemid 43289398)
38. Bouvard D, Millon-Fremillon A, Dupe-Manet S, Block MR, Albiges-Rizo C,. Unraveling ICAP-1 function: toward a new direction? Eur J Cell Biol. 2006; 85: 275-282.
39. Liu S, Calderwood DA, Ginsberg MH,. Integrin cytoplasmic domain-binding proteins. J Cell Sci. 2000; 113: 3563-3571.
40. Chang DD, Wong C, Smith H, Liu J,. ICAP-1, a novel beta1 integrin cytoplasmic domain-associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. J Cell Biol. 1997; 138: 1149-1157. (Pubitemid 27386463)
41. Rodrigues-Lisoni FC, Mehet DK, Peitl P Jr, et al. In vitro and in vivo studies on CCR10 regulation by Annexin A1. FEBS Lett. 2006; 580: 1431-1438. (Pubitemid 43222011)
42. Zhu F, Xu C, Jiang Z, et al. Nuclear localization of annexin A1 correlates with advanced disease and peritoneal dissemination in patients with gastric carcinoma. Anat Rec. 2010; 293: 1310-1314.
43. Lin CY, Jeng YM, Chou HY, et al. Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. J Surg Oncol. 2008; 97: 544-550.